Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Applied Vascular Engineering (US) starts Micro Stent trial

This article was originally published in Clinica

Executive Summary

Applied Vascular Engineering (US) has started US trials of its Micro Stent following receipt of an Investigational Device Exemption from the FDA. SMART (Study of Micro Stent's Ability to Limit Restenosis Trial) will compare Micro Stent to J&J's Palmaz-Schatz stent in de novo lesions at 20 centres. Enrolment of patients is expected to take six months. Like the Benestent II heparin-coated stent trial (see Clinica No 669/70, p 24), SMART includes ticlopidine antiplatelet therapy in its protocol.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel